A buy-out bargain. If we use 174,000,000 as the current outstanding share total with warrants, and attach some per share prices, IMEXF starts to look like a potentential bargain. I have stated before that I want to see this tech in use and saving lives as soon as possible. The fastest pathway to facilitating that goal may be incorporating IMEXF tech in another firm's platform. I am unconvinced at this time that management has command of the complex elements that would be required to launch a startup in this competitive market against well prepared and financed competitors. I do not even want to think about the dilution of shares required to finance a product roll out. Stryker has paid $ 800 million as a large down payment on what they hope will be the market standard system. So what would Stryker potentially pay us for our tech's unique features to complete their product? At $1.00 US per our share their initial combined out-of-pocket is still under a billion USD. That might be very affordable given the size of the global market. But, we can plug in any figure we are willing to consider: .88 USD , .78, .44? Pay me sooner than later and I am prepared to make a deal. I am now averaged at .14 USD, so I am down by half, but I can still see scenarios where this works out just fine. Individual satisfaction will vary by what each shareholder's expectations are.
